Cediranib: A VEGF receptor tyrosine kinase inhibitor

Future Oncology

Volumn 8, Issue 7, 2012, Pages 775-781

  Sahade, Marina ^a   Caparelli, Fernanda ^a   Hoff, Paulo M ^a  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

Author keywords

antiangiogenic; AZD2171; cancer; cediranib; chemotherapy; VEGF

Indexed keywords

BEVACIZUMAB; CEDIRANIB; CYTOTOXIC AGENT; LOMUSTINE;

ALVEOLAR SOFT PART SARCOMA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; COLORECTAL CANCER; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DYSPHONIA; EPITHELIAL OVARIAN CARCINOMA; FATIGUE; GLIOBLASTOMA; HOARSENESS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG CANCER; NAUSEA; OVARY CARCINOMA; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; SINGLE DRUG DOSE; UTERINE TUBE CARCINOMA; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CENTRAL NERVOUS SYSTEM NEOPLASMS; COLORECTAL NEOPLASMS; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; GLIOBLASTOMA; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; OVARIAN NEOPLASMS; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; SARCOMA;

EID: 84864425278     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.73     Document Type: Article

References (32)

1. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275(5302), 964-967 (1997).
2. Gille H, Kowalski J, Li B et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2): A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J. Biol. Chem. 276(5), 3222-3230 (2001).
3. Drevs J, Siegert P, Medinger M et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25(21), 3045-3054 (2007).
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350(23), 2335-2342 (2004).
5. Johnson DH, Fehrenbacher L, Novotny W et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol. 22(11), 2184-2191 (2004).
6. Escudier B. Sorafenib for the management of advanced renal cell carcinoma. Expert Rev. Anticancer Ther. 11(6), 825-836 (2011).
7. Motzer RJ, Michaelson MD, Redman BG et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24(1), 16-24 (2006).
8. Langer CJ, Natale RB. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. Semin. Oncol. 32(6 Suppl. 10), S23-S29 (2005).
9. Achen MG, Stacker SA. Molecular control of lymphatic metastasis. Ann. NY Acad. Sci. 1131, 225-234 (2008).
10. Gomez-Rivera F, Santillan-Gomez AA, Younes MN et al. The tyrosine kinase inhibitor, AZD 2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model. Clin. Cancer Res. 13(15 Pt 1), 4519-4527 (2007).
11. Goss G, Shepherd FA, Laurie S et al. A Phase I and pharmacokinetic study of daily oral cediranib, and inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. Eur. J. Cancer 45(5), 782-788 (2009).
12. Wedge SR, Kendrew J, Hennequin LF et al. AZD2171: A highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 65(10), 4389-4400 (2005).
13. Mitchell CL, O'Connor JP, Roberts C et al. A two-part Phase II study of cediranib in patients with advanced solid tumors: The effect of food on single-dose pharmacokinetics and an evaluation of safety, efficacy and imaging pharmacodynamics. Cancer Chemother. Pharmacol. 68(3), 631-641 (2011).
14. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from Phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol. 3(1), 24-40 (2006).
15. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J. Clin. Oncol. 28(17), 2817-2823 (2010).
16. Robinson ES, Matulonis UA, Ivy P et al. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin. J. Am. Soc. Nephrol. 5(3), 477-483 (2010).
17. Batchelor TT, Mulholland P, Neyns B et al. The efficacy of cediranib as monotherapy and in combination with lomustine compared with lomustine alone in patients with recurrent glioblastoma: A Phase III randomized study. Presented at: PROCEEDINGS of the 2010 Society for Neuro-Oncology Annual Meeting. Montréal, Canada, 18-21 November 2010.
18. Matulonis UA, Berlin S, Ivy P et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J. Clin. Oncol. 27(33), 5601-5606 (2009).
19. Hirte HW, Vidal L, Fleming GF et al. A Phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. Presented at: PROCEEDINGS of the 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
20. Raja FA, Griffin CL, Qian W et al. Initial toxicity assessment of ICON6: A randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br. J. Cancer 105(7), 884-889 (2011).
21. Cunningham D, Wong RP, D'haens G et al. A Phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results. Presented at: PROCEEDINGS of the 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
22. Hoff PM, Hochhaus A, Pestalozzi B et al. Cediranib + FOLFOX/XELOX versus placebo + FOLFOX/XELOX in patients (pts) with previously untreated metastatic colorectal cancer (MCRC): A randomized, double-blind, Phase III study (HORIZON II). Presented at: PROCEEDINGS of the 35th ESMO Congress. Milan, Italy, 8-12 October 2010.
23. Schmoll H, Cunningham D, Sobrero A et al. mFOLFOX6 + cediranib vs. mFOLFOX6 + bevacizumab in previously untreated metastatic colorectal cancer (mCRC): A randomized, double-blind, Phase II/III study (HORIZON III). Presented at: PROCEEDINGS of the 35th ESMO Congress. Milan, Italy, 8-12 October 2010.
24. Robertson JD, Botwood NA, Rothenberg ML, Schmoll HJ. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: horizon III. Clin. Colorectal Cancer 8(1), 59-60 (2009).
25. Goss GD, Arnold A, Shepherd FA et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: ncic clinical trials group BR24 study. J. Clin. Oncol. 28(1), 49-55 (2010).
26. Ramalingam SS, Belani CP, Mack PC et al. Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097). J. Thorac. Oncol. 5(8), 1279-1284 (2010).
27. Gardner K, Judson I, Leahy M et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. Presented at: PROCEEDINGS of the 45th ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
28. Kummar S, Strassberger A, Monks SP et al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). Presented at: PROCEEDINGS of the 47th ASCO Annual Meeting. Chicago, IL, USA, 3-4 June 2011.
29. Sridhar SS, Mackenzie SJ, Hotte SD et al. Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A Phase II trial of the PMH Consortium. Presented at: PROCEEDINGS of the 44th ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008.
30. Mulders P, Hawkins R, Nathan P et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: Results of a randomised Phase II study. Eur. J. Cancer 48(4), 527-537 (2012).
31. Yin JJ, Zhang L, Munasingue J, Linnoila RI, Kelly K. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res. 70(21), 8662-8673 (2010).
32. Najy AJ, Jung YS, Won JJ et al. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction. Prostate doi:10.1002/ pros.22481 (2011) (Epub ahead of print).